oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2016-15-1-26-30oncotomsk-305Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESРЕЗУЛЬТАТЫ ЛЕЧЕНИЯ БОЛЬНЫХ МЕСТНОРАСПРОСТРАНЕННЫМ И МЕТАСТАТИЧЕСКИМ НЕПЛОСКОКЛЕТОЧНЫМ НЕМЕЛКОКЛЕТОЧНЫМ РАКОМ ЛЕГКОГО ПРЕПАРАТОМ ПЕМЕТРЕКСЕД (СОБСТВЕННЫЙ ОПЫТ)RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)ВладимироваЛ. Ю.VladimirovaL. Yu.

доктор медицинских наук, профессор, руководитель отдела лекарственного лечения опухолей, 

344037, г. Ростов-на-Дону, ул. 14-я линия, 63

MD, Professor, Head of the Department of Drug Therapy for Cancer,

63, 14 Line, 344037-Rostov-on-Don

vlu@aaanet.ruСторожаковаА. Э.StorozhakovaA. E.

кандидат медицинских наук, старший научный сотрудник отдела лекарственного лечения опухолей,

344037, г. Ростов-на-Дону, ул. 14-я линия, 63

MD, PhD, Senior Researcher, Department of Drug Therapy for Cancer,

63, 14 Line, 344037-Rostov-on-Don

КабановС. Н.KabanovS. N.

кандидат медицинских наук, старший научный сотрудник отдела лекарственного лечения опухолей, 

344037, г. Ростов-на-Дону, ул. 14-я линия, 63

MD, PhD, Senior Researcher, Department of Drug Therapy for Cancer,

63, 14 Line, 344037-Rostov-on-Don

Introitus@mail.ruКалабановаЕ. А.KalabanovaE. A.

кандидат медицинских наук, старший научный сотрудник отдела лекарственного лечения опухолей, 

344037, г. Ростов-на-Дону, ул. 14-я линия, 63

MD, PhD, Senior Researcher, Department of Drug Therapy for Cancer,

63, 14 Line, 344037-Rostov-on-Don

alenakalabanova@mail.ruФГБУ «Ростовский научно-исследовательский онкологический институт МЗ России»РоссияRostov Research Institute of OncologyRussian Federation2016230420161512630Copyright © Владимирова Л.Ю., Сторожакова А.Э., Кабанов С.Н., Калабанова Е.А., 20162016Владимирова Л.Ю., Сторожакова А.Э., Кабанов С.Н., Калабанова Е.А.Vladimirova L.Y., Storozhakova A.E., Kabanov S.N., Kalabanova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/305

Рак легкого является наиболее распространенным злокачественным новообразованием. В связи с тем, что более 70 % больных на момент постановки диагноза имеют местнораспространенный или генерализованный процесс, основной массе пациентов проводится лекарственное лечение. Оценены эффективность и токсичность препарата пеметрексед (алимта) у 24 больных местнораспространенным и метастатическим неплоскоклеточным немелкоклеточным раком легкого с известным статусом мутации EGFR. Пеметрексед вводился в дозе 500 мг/м2 в монорежиме (8 пациентов) или в сочетании с препаратами платины (16 пациентов). У 3 (12,5 %) пациентов зафиксирована полная регрессия, у 7 (29,2 %) – частичная регрессия, у 10 (41,7 %) – стабилизация, у 4 (16,7 %) – прогрессирование. Медиана продолжительности жизни составила 14,8 мес. Были отмечены негематологические осложнения, как правило, со стороны пищеварительной системы. Среди гематологических осложнений наблюдалась лейкопения I степени – 27 (21,3 %), тромбоцитопения II и III степеней – по 1 (0,8 %) случаю. Осложнения не требовали назначения лекарственных препаратов или корректировались медикаментозно. По нашему опыту пеметрексед продемонстрировал высокую эффективность у больных с неплоскоклеточным НМРЛ в сочетании с низкой частотой возникновения побочных эффектов и контролируемой токсичностью.

Lung cancer is one of the most common malignant tumors. As over 70 % of patients at diagnosis have locally advanced or generalized process, the majority of patients receive drug treatment only. We evaluated effectiveness and toxicity of pemetrexed (Alimta) in 24 patients with locally advanced and metastatic non-squamous cell non-small-cell lung carcinoma with the known EGFR mutation status. Pemetrexed 500 mg/m2 was administered as monotherapy (8 patients) or in combination with platinum-based drugs (15 patients). Three (12.5 %) patients showed complete regression, 7 (29.2 %) – partial regression, 10 (41.7 %) – stabilization, 4 (16.6 %) – progression. The median survival was 14.8 months. Non-hematological complications were registered, usually concerning the digestive system. Hematological complications included first-degree leukopenia – 27 (21.3 %), second- and third-degree thrombocytopenia – 1 case of each (0.8%). The complications did not require administration of drugs or were corrected medicamentally. We observed a high effectiveness of pemetrexed in patients with non-squamous NSCLC, as well as a low rate of complications and controlled toxicity.

немелкоклеточный рак легкогоаденокарцинома легкогомутация EGFRхимиотерапияпеметрекседnon-small-cell lung canceradenocarcinoma of the lungEGFR mutationchemotherapypemetrexedReferencesВладимирова Л.Ю., Кит О.И., Шолохова Е.А. Роль гистологического и молекулярного анализа в выборе метода лечения немелкоклеточного рака легкого поздних стадий // Фарматека. 2012. № 8. С. 9–22.Vladimirova L.Yu., Kit O.I., Sholokhova E.A. The role of the histological and molecular analysis in choosing the method of treatment NSCLC late stages // Farmateka. 2012. № 8. P. 10–23. [in Rissian]Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М., 2013.Davydov M.I., Aksel’ E.M. Statistics malignancies in Russia and the CIS countries in 2012. М., 2013. [in Rissian] 3. Kit O.I., Vladimirova L.Yu., Sholokhova E.A. Efficacy and safety ofpemetrexed maintenance therapy in advanced non-small-cell lung cancer: a review of phase III studies // Sovremennaja onkologija. 2013. Vol. 15 (1). P. 27–31. [in Rissian]Кит О.И., Владимирова Л.Ю., Шолохова Е.А. Эффективность и профиль безопасности поддерживающей терапии пеметрекседом при немелкоклеточном раке легкого поздних стадий: обзор исследований III фазы // Современная онкология. 2013. Т. 15, № 1. С. 27–31.Azzoli C.G., Temin S., Aliff T., Baker S. Jr., Brahmer J., Johnson D.H., Laskin J.L., Masters G., Milton D., Nordquist L., Pao W., Pfister D.G., Piantadosi S., Schiller J.H., Smith R., Smith T.J., Strawn J.R., Trent D., Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer // J. Clin. Oncol. 2011. Vol. 29 (28). P. 3825–3831. doi: 10.1200/JCO.2010.34.2774Azzoli C.G., Temin S., Aliff T., Baker S. Jr., Brahmer J., Johnson D.H., Laskin J.L., Masters G., Milton D., Nordquist L., Pao W., Pfister D.G., Piantadosi S., Schiller J.H., Smith R., Smith T.J., Strawn J.R., Trent D., Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer // J. Clin. Oncol. 2011. Vol. 29 (28). P. 3825–3831. doi: 10.1200/JCO.2010.34.2774D’Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow up // Ann. Oncol. 2010. Vol. 21 (Suppl. 5): v116–9. doi: 10.1093/annonc/mdq189.D’Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow up // Ann. Oncol. 2010. Vol. 21 (Suppl. 5): v116–9. doi: 10.1093/annonc/mdq189.Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) // Eur. J. Cancer. 2009. Vol. 45 (2). P. 228–247. doi: 10.1016/j.ejca.2008.10.026.Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) // Eur. J. Cancer. 2009. Vol. 45 (2). P. 228–247. doi: 10.1016/j.ejca.2008.10.026.International Agensy for Research on Cancer (2013) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 (http:// globocan. iarc. fr / Default. aspx).International Agensy for Research on Cancer (2013) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 (http:// globocan. iarc. fr / Default. aspx).Giorgio C.G., Pappalardo A., Russo A., Giuffrida D., Santini D., Petralia G., Castorina S., Nunzio R., Failla G., Bordonaro R. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) // Lung Cancer. 2006. Vol. 51 (3). P. 357–362.Giorgio C.G., Pappalardo A., Russo A., Giuffrida D., Santini D., Petralia G., Castorina S., Nunzio R., Failla G., Bordonaro R. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) // Lung Cancer. 2006. Vol. 51 (3). P. 357–362.Gridelli C., Maione P., Rossi A., Ferrara M.L., Bareschino M.A., Schettino C., Sacco P.C., Ciardiello F. Potential treatment options after firstline chemotherapy for advanced NSCLC: maintenance treatment or early second-line? // Oncologist. 2009. Vol. 14 (2). P. 137–147. doi: 10.1634/theoncologist.2008-0152.Gridelli C., Maione P., Rossi A., Ferrara M.L., Bareschino M.A., Schettino C., Sacco P.C., Ciardiello F. Potential treatment options after firstline chemotherapy for advanced NSCLC: maintenance treatment or early second-line? // Oncologist. 2009. Vol. 14 (2). P. 137–147. doi: 10.1634/theoncologist.2008-0152.Grossi F., Aita M., Follador A., Defferrari C., Brianti A., Sinaccio G., Belvedere O. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature // Oncologist. 2007. Vol. 12 (4). P. 451–464.Grossi F., Aita M., Follador A., Defferrari C., Brianti A., Sinaccio G., Belvedere O. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature // Oncologist. 2007. Vol. 12 (4). P. 451–464.Ozols R.F., Herbst R.S., Colson Y.L., Gralow J., Bonne J., Curran W.J., Eisenberg B.L., Ganz P.A., Kramer B.S., Kris M.G., Markman M., Mayer R.J., Raghavan D., Reaman G.H., Sawaya R., Schilsky R.L., Schuchter L.M., Sweetenham J.W., Vahdat L.T., Winn R.J. Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention and Screening – A Report From the American Society of Clinical Oncology // JCO. 2007. Vol. 25 (1). P. 146–162.Ozols R.F., Herbst R.S., Colson Y.L., Gralow J., Bonne J., Curran W.J., Eisenberg B.L., Ganz P.A., Kramer B.S., Kris M.G., Markman M., Mayer R.J., Raghavan D., Reaman G.H., Sawaya R., Schilsky R.L., Schuchter L.M., Sweetenham J.W., Vahdat L.T., Winn R.J. Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention and Screening – A Report From the American Society of Clinical Oncology // JCO. 2007. Vol. 25 (1). P. 146–162.Peterson P., Park K., Fossella F. et al. Is pemetrexed more effective in Adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advance non-small cell lung cancer (NSCLC) // J. Thorac. Oncol. 2007. Vol. 2 (4): S851 (abstract P2-238).Peterson P., Park K., Fossella F. et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advance non-small cell lung cancer (NSCLC) // J. Thorac. Oncol. 2007. Vol. 2 (4): S851 (abstract P2-238).Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., de Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Muñoz-Langa J., Valdivia J., Isla D., Domine M., Molinier O., Mazieres J., Baize N., Garcia-Campelo R., Robinet G., Rodriguez-Abreu D., Lopez-Vivanco G., Gebbia V., Ferrera-Delgado L., Bombaron P., Bernabe R., Bearz A., Artal A., Cortesi E., Rolfo C., Sanchez-Ronco M., Drozdowskyj A., Queralt C., de Aguirre I., Ramirez J.L., Sanchez J.J., Molina M.A., Taron M., PazAres L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial // Lancet Oncol. 2012. Vol. 13. P. 239–246. doi: 10.1016/S1470-2045(11)70393-X.Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., de Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Muñoz-Langa J., Valdivia J., Isla D., Domine M., Molinier O., Mazieres J., Baize N., Garcia-Campelo R., Robinet G., Rodriguez-Abreu D., Lopez-Vivanco G., Gebbia V., Ferrera-Delgado L., Bombaron P., Bernabe R., Bearz A., Artal A., Cortesi E., Rolfo C., Sanchez-Ronco M., Drozdowskyj A., Queralt C., de Aguirre I., Ramirez J.L., Sanchez J.J., Molina M.A., Taron M., PazAres L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial // Lancet Oncol. 2012. Vol. 13. P. 239–246. doi: 10.1016/S1470-2045(11)70393-X.Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification // J. Thorac. Oncol. 2011. Vol. 6 (9).P. 1496–1504. doi: 10.1097/JTO.0b013e318221f701. 15. Scagliotti G., Kortsik C., Dark G.G., Price A., Manegold C., Rosell R.,Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification // J. Thorac. Oncol. 2011. Vol. 6 (9). P. 1496–1504. doi: 10.1097/JTO.0b013e318221f701.O’Brien M., Peterson P.M., Castellano D., Selvaggi G., Novello S., Blatter J., Kayitalire L., Crino L., Paz-Ares L. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized, phase II trial // Clin. Cancer Res. 2005. Vol. 11. P. 690–696.Scagliotti G., Kortsik C., Dark G.G., Price A., Manegold C., Rosell R., O’Brien M., Peterson P.M., Castellano D., Selvaggi G., Novello S., Blatter J., Kayitalire L., Crin L., Paz-Ares L. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized, phase II trial // Clin. Cancer Res. 2005. Vol. 11. P. 690–696.Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de Marinis F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer // J. Clin. Oncol. 2008. Vol. 26 (21). P. 3543–3551. doi: 10.1200/JCO.2007.15.0375.Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de Marinis F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer // J. Clin. Oncol. 2008. Vol. 26 (21). P. 3543–3551. doi: 10.1200/JCO.2007.15.0375.Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., Simms L., Shepherd F.A. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies // Oncologist. 2009. Vol. 14 (3). P. 253–263. doi: 10.1634/theoncologist.2008-0232.Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., Simms L., Shepherd F.A. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies // Oncologist. 2009. Vol. 14 (3). P. 253–263. doi: 10.1634/theoncologist.2008-0232.Shepherd F.A., Dancey J., Arnold A., Neville A., Rusthoven J., Johnson R.D., Fisher B., Eisenhauer E. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin in patients as first-line therapy in patients with advanced non-small cell lung cancer: a study of National Cancer Institute of Canada clinical trials group // Cancer. 2001. Vol. 92. P. 595–600.Shepherd F.A., Dancey J., Arnold A., Neville A., Rusthoven J., Johnson R.D., Fisher B., Eisenhauer E. Phase II study of pemetrexed disodium, a multitargeted antifolate, and displatin in patients as first-line therapy in patients with advanced non-small cell lung cancer: a study of National Cancer Institute of Canada clinical trials group // Cancer. 2001. Vol. 92. P. 595–600.Socinski M.A., Smit E.F., Lorigan P., Konduri K., Reck M., Szczesna A., Blakely J., Serwatowski P., Karaseva N.A., Ciuleanu T., Jassem J., Dediu M., Hong S., Visseren-Grul C., Hanauske A.R., Obasaju C.K., Guba S.C., Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small cell lung cancer // J. Clin. Oncol.2009. Vol. 27 (28). P. 4787–4792. doi: 10.1200/JCO.2009.23.1548.Socinski M.A., Smit E.F., Lorigan P., Konduri K., Reck M., Szczesna A., Blakely J., Serwatowski P., Karaseva N.A., Ciuleanu T., Jassem J., Dediu M., Hong S., Visseren-Grul C., Hanauske A.R., Obasaju C.K., Guba S.C., Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small cell lung cancer // J. Clin. Oncol. 2009. Vol. 27 (28). P. 4787–4792. doi: 10.1200/JCO.2009.23.1548.Stinchcombe T.E., Socinski M.A. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy // J. Thorac. Oncol. 2009. Vo. 4 (2). P. 243–250. doi: 10.1097/JTO.0b013e31819516a6.Stinchcombe T.E., Socinski M.A. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy // J. Thorac. Oncol. 2009. Vo. 4 (2). P. 243–250. doi: 10.1097/JTO.0b013e31819516a6.Zhang W., Guo N., Yu C., Wang H., Zhang Y., Xia H., Yu J., Lu J. Differencial expression of ERCC1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma // Tumor Biol. 2012. Vol. 33. P. 2209–2216. doi: 10.1007/s13277-012-0482-4.Zhang W., Guo N., Yu C., Wang H., Zhang Y., Xia H., Yu J., Lu J. Differencial expression of ERCC1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma // Tumor Biol. 2012. Vol. 33. P. 2209–2216. doi: 10.1007/s13277-012-0482-4.Zhang W., Guo N., Yu C., Wang H., Zhang Y., Xia H., Yu J., Lu J. Differencial expression of ERCC1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma // Tumor Biol. 2012. Vol. 33. P. 2209–2216. doi: 10.1007/s13277-012-0482-4.

The authors declare that there are no conflicts of interest present.